

**AMENDMENTS TO THE CLAIMS:**

The following listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1 (previously presented) A composition comprising a monoclonal antibody wherein the monoclonal antibody is produced by the KKO hybridoma cell line deposited under ATCC No.: PTA-6133.

Claim 2 (previously presented) The composition of claim 1, wherein the monoclonal antibody is capable of binding specifically with platelet factor 4 (PF4)/heparin complex, wherein the monoclonal antibody preferentially binds with the PF4/heparin complex relative to a binding with either PF4 or heparin alone.

Claim 3 (previously presented) The composition of claim 1, wherein the monoclonal antibody activates platelets through a PF4/heparin dependent mechanism.

Claim 4 (cancelled)

Claim 5 (previously presented) The composition of claim 1, wherein the monoclonal antibody is a murine monoclonal antibody.

Claim 6-41 (cancelled)

Claim 42 (previously presented) A hybridoma cell line deposited as ATCC No.: PTA-6133.

Claim 43 (previously presented) A monoclonal antibody produced by a hybridoma cell line deposited as ATCC No.: PTA-6133.

Claims 44-46 (canceled)